文献速递呼吸衰竭与机械通气儿科与产科急症重症综合管理与镇静镇痛

高流量鼻导管通气与持续气道正压通气对儿科重症监护病房急性病患儿呼吸支持脱离时间的影响:一项随机临床试验

Effect of High-Flow Nasal Cannula Therapy vs Continuous Positive Airway Pressure Therapy on Liberation From Respiratory Support in Acutely Ill Children Admitted to Pediatric Critical Care Units: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2022-01-01
一句话结论在儿科重症监护病房需无创呼吸支持的急性病患儿中,高流量鼻导管通气相比持续气道正压通气在脱离呼吸支持时间上达到非劣效标准。

这项在24个儿科重症监护病房开展的实用型多中心随机非劣效试验纳入600名0至15岁急性病患儿,随机接受高流量鼻导管通气(按体重设定流量)或持续气道正压通气7至8 cm H2O。主要终点为随机化至脱离所有形式呼吸支持的时间,非劣效界值为调整风险比0.75。高流量组中位脱离时间52.9小时 vs 持续气道正压组47.9小时,调整风险比1.03(单侧97.5%CI 0.86-∞),达到非劣效标准。高流量组镇静使用、重症监护病房停留时间和急性住院时间均显著更低。

要点

  • 在24个儿科重症监护病房的600名急性病患儿中,高流量鼻导管通气相比持续气道正压通气在脱离呼吸支持时间上达到非劣效(调整风险比1.03,单侧97.5%CI 0.86-∞,非劣效界值0.75)。
  • 高流量组中位脱离时间52.9小时(95%CI 46.0-60.9)vs 持续气道正压组47.9小时(95%CI 40.5-55.7),绝对差异5.0小时(95%CI -10.1至17.4)。
  • 高流量组镇静使用率27.7% vs 持续气道正压组37%,调整比值比0.59(95%CI 0.39-0.88)。
  • 高流量组平均重症监护病房停留时间5天 vs 持续气道正压组7.4天,调整均值差-3天(95%CI -5.1至-1天);平均急性住院时间13.8天 vs 19.5天,调整均值差-7.6天(95%CI -13.2至-1.9天)。
  • 最常见不良事件为鼻部损伤:高流量组6/295(2.0%)vs 持续气道正压组18/278(6.5%)。

适用人群与场景

  • 0至15岁急性病患儿,经临床评估需要无创呼吸支持,入住儿科重症监护病房。
  • 招募时间2019年8月至2021年11月,末次随访2022年3月完成。

诊断标准与关键阈值

  • 主要终点脱离呼吸支持定义为开始连续48小时无任何形式呼吸支持(有创或无创)的起始时间。
  • 非劣效界值为调整风险比0.75。

处置流程与药物剂量

  • 高流量鼻导管通气组(n=301):流量根据患者体重设定(原文未写明具体流量数值)。
  • 持续气道正压通气组(n=299):持续气道正压7至8 cm H2O。

研究设计与关键结果

  • 实用型多中心随机非劣效临床试验,在24个儿科重症监护病房开展,纳入600名0至15岁急性病患儿,随机1:1接受高流量鼻导管通气(n=301)或持续气道正压通气7至8 cm H2O(n=299)。
  • 主要分析纳入573名患儿(高流量组295名,持续气道正压组278名;中位年龄9个月;226名女孩[39%])。
  • 主要终点:高流量组中位脱离时间52.9小时(95%CI 46.0-60.9)vs 持续气道正压组47.9小时(95%CI 40.5-55.7),绝对差异5.0小时(95%CI -10.1至17.4),调整风险比1.03(单侧97.5%CI 0.86-∞),达到非劣效标准。
  • 7个预设次要终点中3个在高流量组显著更低:镇静使用率27.7% vs 37%(调整比值比0.59[95%CI 0.39-0.88]);平均重症监护病房停留时间5天 vs 7.4天(调整均值差-3天[95%CI -5.1至-1天]);平均急性住院时间13.8天 vs 19.5天(调整均值差-7.6天[95%CI -13.2至-1.9天])。
  • 最常见不良事件为鼻部损伤:高流量组6/295(2.0%)vs 持续气道正压组18/278(6.5%)。

证据类型、等级与局限

  • 证据类型:实用型多中心随机非劣效临床试验(24个儿科重症监护病房)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于儿科重症监护病房中经临床评估需要无创呼吸支持的急性病患儿(0至15岁),高流量鼻导管通气可作为持续气道正压通气之外的首次无创呼吸支持选择,因为达到非劣效标准且镇静使用、重症监护病房停留和急性住院时间更低。
  • 高流量鼻导管通气流量需根据患者体重设定,持续气道正压通气压力为7至8 cm H2O。
  • 高流量鼻导管通气组鼻部损伤发生率2.0%,持续气道正压通气组6.5%。

指南或共识出处

  • 试验注册:ISRCTN.org Identifier: ISRCTN60048867。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: The optimal first-line mode of noninvasive respiratory support for acutely ill children is not known.

OBJECTIVE: To evaluate the noninferiority of high-flow nasal cannula therapy (HFNC) as the first-line mode of noninvasive respiratory support for acute illness, compared with continuous positive airway pressure (CPAP), for time to liberation from all forms of respiratory support.

DESIGN, SETTING, AND PARTICIPANTS: Pragmatic, multicenter, randomized noninferiority clinical trial conducted in 24 pediatric critical care units in the United Kingdom among 600 acutely ill children aged 0 to 15 years who were clinically assessed to require noninvasive respiratory support, recruited between August 2019 and November 2021, with last follow-up completed in March 2022.

INTERVENTIONS: Patients were randomized 1:1 to commence either HFNC at a flow rate based on patient weight (n = 301) or CPAP of 7 to 8 cm H2O (n = 299).

MAIN OUTCOMES AND MEASURES: The primary outcome was time from randomization to liberation from respiratory support, defined as the start of a 48-hour period during which a participant was free from all forms of respiratory support (invasive or noninvasive), assessed against a noninferiority margin of an adjusted hazard ratio of 0.75. Seven secondary outcomes were assessed, including mortality at critical care unit discharge, intubation within 48 hours, and use of sedation.

RESULTS: Of the 600 randomized children, consent was not obtained for 5 (HFNC: 1; CPAP: 4) and respiratory support was not started in 22 (HFNC: 5; CPAP: 17); 573 children (HFNC: 295; CPAP: 278) were included in the primary analysis (median age, 9 months; 226 girls [39%]). The median time to liberation in the HFNC group was 52.9 hours (95% CI, 46.0-60.9 hours) vs 47.9 hours (95% CI, 40.5-55.7 hours) in the CPAP group (absolute difference, 5.0 hours [95% CI -10.1 to 17.4 hours]; adjusted hazard ratio 1.03 [1-sided 97.5% CI, 0.86-∞]). This met the criterion for noninferiority. Of the 7 prespecified secondary outcomes, 3 were significantly lower in the HFNC group: use of sedation (27.7% vs 37%; adjusted odds ratio, 0.59 [95% CI, 0.39-0.88]); mean duration of critical care stay (5 days vs 7.4 days; adjusted mean difference, -3 days [95% CI, -5.1 to -1 days]); and mean duration of acute hospital stay (13.8 days vs 19.5 days; adjusted mean difference, -7.6 days [95% CI, -13.2 to -1.9 days]). The most common adverse event was nasal trauma (HFNC: 6/295 [2.0%]; CPAP: 18/278 [6.5%]).

CONCLUSIONS AND RELEVANCE: Among acutely ill children clinically assessed to require noninvasive respiratory support in a pediatric critical care unit, HFNC compared with CPAP met the criterion for noninferiority for time to liberation from respiratory support.

TRIAL REGISTRATION: ISRCTN.org Identifier: ISRCTN60048867.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Ramnarayan P, Richards-Belle A, Drikite L, et al. Effect of High-Flow Nasal Cannula Therapy vs Continuous Positive Airway Pressure Therapy on Liberation From Respiratory Support in Acutely Ill Children Admitted to Pediatric Critical Care Units: A Randomized Clinical Trial. JAMA. 2022. PMID: 35707984. doi:10.1001/jama.2022.9615

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。